SS
FATE icon

Sunbelt Securities’s Fate Therapeutics FATE Stock Holding History

Sunbelt Securities’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$109 Buy
91
+61
+203% +$74 ﹤0.01% 2634
2025
Q4 		$29 Buy
+30
New +$36 ﹤0.01% 2700

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sunbelt Securities's FATE Position: Q1 2026 in Review

Sunbelt Securities increased its Fate Therapeutics (FATE) stake by 203% in Q1 2026, buying an estimated $74 and bringing the position to 91 shares worth $109. The position accounts for ﹤0.01% of the portfolio, ranked #2634.

Sunbelt Securities first reported a position in FATE in Q4 2025 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Sunbelt Securities held 91 shares of Fate Therapeutics worth $109 as of Q1 2026.
  • Sunbelt Securities bought 61 Fate Therapeutics shares in Q1 2026, an estimated $74.
  • Fate Therapeutics made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2634 holding.
  • Sunbelt Securities first reported a position in Fate Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.